A uniform conditioning regimen of busulfan, fludarabine, and antithymocyte globulin for allogeneic haematopoietic cell transplantation from haploidentical family, matched sibling, or unrelated donors—A single‐centre, prospective, explorative study
暂无分享,去创建一个
Su Mi Kim | Je-Hwan Lee | Jung-Hee Lee | K. Lee | Hyeran Kang | Young-Shin Lee | M. Jeon | Han-Seung Park | Eun-Ji Choi | Y. Choi | J. Woo | Y. Kang | Seunghyun Baek | Chae-Eun Bong | S. Baek | Young-Ah Kang
[1] D. Blaise,et al. Clinical Significance of Haplo-Fever and Cytokine Profiling After Graft Infusion in Allogeneic Stem Cell Transplantation From Haplo-Identical Donors , 2022, Frontiers in Medicine.
[2] P. Chiusolo,et al. Triple post transplant cyclophosphamide (PTCY) based GVHD prophylaxis: HLA matched versus HLA haploidentical transplants , 2022, Bone Marrow Transplantation.
[3] R. Soiffer,et al. HLA-haploidentical vs matched unrelated donor transplants with posttransplant cyclophosphamide-based prophylaxis. , 2021, Blood.
[4] R. Soiffer,et al. HLA Haploidentical versus Matched Unrelated Donor Transplants with Post-Transplant Cyclophosphamide based prophylaxis. , 2021, Blood.
[5] L. Luznik,et al. PTCy and “The Story of the Three Bears” , 2020, Bone Marrow Transplantation.
[6] M. Labopin,et al. Post-transplant cyclophosphamide versus anti-thymocyte globulin for graft-versus-host disease prevention in haploidentical transplantation for adult acute lymphoblastic leukemia , 2020, Haematologica.
[7] Shannon R. McCurdy,et al. Early Fever after Haploidentical Bone Marrow Transplantation Correlates with Class II HLA-Mismatching and Myeloablation but Not Outcomes. , 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[8] S. Yun,et al. Reduced-Intensity Conditioning with Busulfan, Fludarabine, and Antithymocyte Globulin for Hematopoietic Cell Transplantation from Unrelated or Haploidentical Family Donors in Patients with Acute Myeloid Leukemia in Remission. , 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[9] M. Labopin,et al. Post-transplant cyclophosphamide versus anti-thymocyte globulin as graft- versus-host disease prophylaxis in haploidentical transplant , 2017, Haematologica.
[10] G. Rosner,et al. Prospective study of nonmyeloablative, HLA-mismatched unrelated BMT with high-dose posttransplantation cyclophosphamide. , 2017, Blood advances.
[11] T. Panzarella,et al. Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial. , 2016, The Lancet. Oncology.
[12] Giuseppe Milone,et al. Antilymphocyte Globulin for Prevention of Chronic Graft-versus-Host Disease. , 2016, The New England journal of medicine.
[13] Y. Kanda,et al. Unmanipulated Haploidentical Reduced-Intensity Stem Cell Transplantation Using Fludarabine, Busulfan, Low-Dose Antithymocyte Globulin, and Steroids for Patients in Non-Complete Remission or at High Risk of Relapse: A Prospective Multicenter Phase I/II Study in Japan. , 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[14] Yu Wang,et al. Haploidentical vs identical-sibling transplant for AML in remission: a multicenter, prospective study. , 2015, Blood.
[15] Shannon R. McCurdy,et al. Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide. , 2015, Blood.
[16] T. Lamparelli,et al. Unmanipulated haploidentical bone marrow transplantation and posttransplantation cyclophosphamide for hematologic malignancies after myeloablative conditioning. , 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[17] B. Cho,et al. Comparison of allogeneic stem cell transplantation from familial-mismatched/haploidentical donors and from unrelated donors in adults with high-risk acute myelogenous leukemia. , 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[18] S. Yun,et al. Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome. , 2011, Blood.
[19] N. Kröger,et al. HLA-mismatched unrelated donors as an alternative graft source for allogeneic stem cell transplantation after antithymocyte globulin-containing conditioning regimen. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[20] Je-Hwan Lee,et al. Hematopoietic cell transplantation from an HLA-mismatched familial donor is feasible without ex vivo-T cell depletion after reduced-intensity conditioning with busulfan, fludarabine, and antithymocyte globulin. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[21] Allen R. Chen,et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. , 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[22] Shunichi Kato,et al. High-risk HLA allele mismatch combinations responsible for severe acute graft-versus-host disease and implication for its molecular mechanism. , 2007, Blood.
[23] M. Mohty,et al. Mechanisms of action of antithymocyte globulin: T-cell depletion and beyond , 2007, Leukemia.
[24] I. Kawase,et al. Unmanipulated HLA 2-3 antigen-mismatched (haploidentical) stem cell transplantation using nonmyeloablative conditioning. , 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[25] Yu-Hong Chen,et al. Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation. , 2006, Blood.
[26] H. Chi,et al. Peri-engraftment clinical abnormalities following allogeneic hematopoietic cell transplantation: a retrospective review of 216 patients , 2003, Bone Marrow Transplantation.
[27] C. Schmoor,et al. Matched and mismatched allogeneic stem-cell transplantation from unrelated donors using combined graft-versus-host disease prophylaxis including rabbit anti-T lymphocyte globulin. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] E Lanino,et al. Bone marrow transplantation from unrelated donors: the impact of mismatches with substitutions at position 116 of the human leukocyte antigen class I heavy chain. , 2001, Blood.
[29] T. Spitzer. Engraftment syndrome following hematopoietic stem cell transplantation , 2001, Bone Marrow Transplantation.
[30] P. Ljungman,et al. Low incidence of acute graft-versus-host disease, using unrelated HLA-A-, HLA-B-, and HLA-DR-compatible donors and conditioning, including anti-T-cell antibodies. , 1998, Transplantation.
[31] P. Henslee-Downey,et al. Use of partially mismatched related donors extends access to allogeneic marrow transplant. , 1997, Blood.
[32] J P Klein,et al. Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] A. Delannoy,et al. Clinical evidence for an engraftment syndrome associated with early and steep neutrophil recovery after autologous blood stem cell transplantation. , 1996, Bone marrow transplantation.
[34] K. Sullivan,et al. Second marrow transplants in patients with aplastic anemia rejecting the first graft: use of a conditioning regimen including cyclophosphamide and antithymocyte globulin. , 1987, Blood.
[35] R. Storb,et al. Marrow transplantation from related donors other than HLA-identical siblings. , 1985, The New England journal of medicine.
[36] D. Hedley,et al. MISMATCHED FAMILY DONORS FOR BONE-MARROW TRANSPLANTATION AS TREATMENT FOR ACUTE LEUKAEMIA , 1983, The Lancet.
[37] L. Robison,et al. A randomized study of the prevention of acute graft-versus-host disease. , 1982, The New England journal of medicine.
[38] Eleanor or Mure. The story of the three bears , 1967 .